Total Payments
$175,623
2024 Payments
$303.73
Companies
21
Transactions
186
Medicare Patients
733
Medicare Billing
$234,172
Payment Breakdown by Category
Other$88,190 (50.2%)
Consulting$38,416 (21.9%)
Research$25,710 (14.6%)
Travel$19,247 (11.0%)
Food & Beverage$4,060 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $77,279 | 44 | 44.0% |
| Consulting Fee | $38,416 | 16 | 21.9% |
| Unspecified | $25,710 | 12 | 14.6% |
| Travel and Lodging | $19,247 | 42 | 11.0% |
| Honoraria | $5,500 | 2 | 3.1% |
| Food and Beverage | $4,060 | 67 | 2.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,043 | 2 | 1.7% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,368 | 1 | 1.3% |
Payments by Type
General
$149,913
174 transactions
Research
$25,710
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $121,259 | 108 | $0 (2023) |
| Celgene Corporation | $31,312 | 21 | $0 (2019) |
| Agios Pharmaceuticals, Inc. | $6,807 | 14 | $0 (2019) |
| Servier Pharmaceuticals LLC | $4,403 | 3 | $0 (2021) |
| ACCURAY INCORPORATED | $3,509 | 4 | $0 (2023) |
| Stemline Therapeutics Inc. | $3,393 | 4 | $0 (2023) |
| Kite Pharma, Inc. | $1,875 | 3 | $0 (2021) |
| Daiichi Sankyo Inc. | $1,485 | 8 | $0 (2024) |
| Servier BioInnovation | $573.52 | 2 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $383.07 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $303.73 | 7 | Astellas Pharma US Inc ($153.98) |
| 2023 | $18,900 | 28 | Amgen Inc. ($14,481) |
| 2022 | $3,689 | 12 | Amgen Inc. ($2,174) |
| 2021 | $13,042 | 11 | Amgen Inc. ($6,738) |
| 2020 | $11,260 | 7 | Amgen Inc. ($7,960) |
| 2019 | $39,327 | 39 | Amgen Inc. ($31,893) |
| 2018 | $35,676 | 36 | Amgen Inc. ($21,071) |
| 2017 | $53,427 | 46 | Amgen Inc. ($36,942) |
All Payment Transactions
186 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $14.18 | General |
| Category: ONCOLOGY | ||||||
| 08/09/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $153.98 | General |
| Category: Oncology | ||||||
| 06/04/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $30.40 | General |
| Category: Oncology | ||||||
| 04/22/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $26.79 | General |
| Category: ONCOLOGY | ||||||
| 04/02/2024 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Food and Beverage | In-kind items and services | $25.28 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 03/12/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $31.21 | General |
| Category: Oncology | ||||||
| 01/08/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $21.89 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2023 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $10.47 | General |
| 11/15/2023 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $10.71 | General |
| 11/15/2023 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $1.27 | General |
| 11/13/2023 | Amgen Inc. | Blincyto (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: Oncology | ||||||
| 11/08/2023 | Amgen Inc. | Blincyto (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 11/06/2023 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $29.37 | General |
| Category: Oncology | ||||||
| 10/04/2023 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $6.67 | General |
| Category: Iron Deficiency Anemia | ||||||
| 10/03/2023 | ACCURAY INCORPORATED | Tomo Therapy System (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,292.86 | General |
| Category: RADIATION ONCOLOGY | ||||||
| 09/13/2023 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $10.12 | General |
| 08/25/2023 | Servier BioInnovation | Tibsovo (Drug) | — | Cash or cash equivalent | $411.76 | Research |
| Study: A PHASE I, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION, SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC, AND CLINICAL ACTIVITY STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES WITH AN IDH1 MUTATION • Category: Oncology | ||||||
| 07/27/2023 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $17.96 | General |
| Category: Hematology/Oncology | ||||||
| 06/10/2023 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $32.27 | General |
| Category: Oncology | ||||||
| 06/07/2023 | Servier BioInnovation | Tibsovo (Drug) | — | Cash or cash equivalent | $161.76 | Research |
| Study: A PHASE I, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION, SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC, AND CLINICAL ACTIVITY STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES WITH AN IDH1 MUTATION • Category: Oncology | ||||||
| 05/17/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $23.27 | General |
| Category: Rare Disease | ||||||
| 05/17/2023 | Amgen Inc. | Blincyto (Biological), Kyprolis | Food and Beverage | In-kind items and services | $3.28 | General |
| Category: Oncology | ||||||
| 04/07/2023 | Amgen Inc. | Blincyto (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $275.00 | General |
| Category: Oncology | ||||||
| 04/05/2023 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,410.00 | General |
| 03/30/2023 | Amgen Inc. | Blincyto (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Ph+ R/R ALL historical comparator study | Amgen Inc. | $4,678 | 1 |
| AG-221-C-001 | Celgene Corporation | $3,972 | 1 |
| Targeting MCL-1 in Hematologic Malignancies: Rationale and Progress | Amgen Inc. | $3,767 | 1 |
| AG-221-C-001 - A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hemat | Celgene Corporation | $3,007 | 1 |
| A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation (AG-221-C-001) | Celgene Corporation | $2,866 | 1 |
| AG-221-AML-005 - Phase IIA AG-221-AML-005 (BMS Study Number: CA067-P12) | Celgene Corporation | $1,966 | 1 |
| AG-221-AML-005 | Celgene Corporation | $1,880 | 1 |
| Benefit-risk assessment of blinatumomab in the treatment of relapsed/refractory B-cell precursor acute lymphoblastic leukemia | Amgen Inc. | $1,404 | 1 |
| Systematc Literature Review for Transplant Outcomes among ALL patients with MRD post transplantatio | Amgen Inc. | $1,220 | 1 |
| A PHASE I, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION, SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC, AND CLINICAL ACTIVITY STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES WITH AN IDH1 MUTATION | Servier BioInnovation | $573.52 | 2 |
| Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia | Amgen Inc. | $377.36 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 152 | 664 | $183,012 | $50,114 |
| 2022 | 5 | 154 | 686 | $181,427 | $56,270 |
| 2021 | 5 | 202 | 796 | $196,534 | $63,548 |
| 2020 | 5 | 225 | 1,076 | $223,153 | $64,241 |
Total Patients
733
Total Services
3,222
Medicare Billing
$234,172
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 76 | 353 | $90,368 | $28,061 | 31.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 34 | 224 | $64,667 | $14,860 | 23.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 18 | 26 | $9,880 | $3,035 | 30.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 28 | $12,157 | $2,793 | 23.0% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 13 | 33 | $5,941 | $1,365 | 23.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 73 | 378 | $96,768 | $30,776 | 31.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 35 | 227 | $61,517 | $18,398 | 29.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 13 | 21 | $7,980 | $2,614 | 32.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 19 | 43 | $8,299 | $2,541 | 30.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 14 | 17 | $6,863 | $1,941 | 28.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 81 | 373 | $95,488 | $31,432 | 32.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 37 | 230 | $62,330 | $20,518 | 32.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 51 | 130 | $21,710 | $6,696 | 30.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 17 | 40 | $7,720 | $2,482 | 32.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 16 | 23 | $9,286 | $2,419 | 26.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 45 | 258 | $69,918 | $23,478 | 33.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 102 | 549 | $91,683 | $22,522 | 24.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 38 | 170 | $32,810 | $10,508 | 32.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 28 | 76 | $19,456 | $5,084 | 26.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 12 | 23 | $9,286 | $2,649 | 28.5% |
About Dr. Anthony Stein, MD
Dr. Anthony Stein, MD is a Internal Medicine healthcare provider based in Duarte, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1225046147.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anthony Stein, MD has received a total of $175,623 in payments from pharmaceutical and medical device companies, with $303.73 received in 2024. These payments were reported across 186 transactions from 21 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($77,279).
As a Medicare-enrolled provider, Stein has provided services to 733 Medicare beneficiaries, totaling 3,222 services with total Medicare billing of $234,172. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology, Hematology
- Location Duarte, CA
- Active Since 08/04/2006
- Last Updated 03/23/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1225046147
Products in Payments
- Blincyto (Biological) $99,787
- Revlimid (Drug) $17,448
- Idhifa (Drug) $13,800
- TIBSOVO (Drug) $11,210
- Kyprolis (Biological) $5,927
- ELZONRIS (Drug) $3,393
- Tomo Therapy System (Device) $2,293
- Tecartus (Drug) $1,875
- TomoTherapy System (Device) $1,216
- Tibsovo (Drug) $573.52
- XGEVA (Biological) $450.10
- TASIGNA (Drug) $292.09
- Xospata (Drug) $153.98
- REZUROCK (Drug) $125.68
- SCEMBLIX (Drug) $90.98
- CC-486 (Drug) $64.29
- VYXEOS (Drug) $51.31
- ULTOMIRIS (Biological) $45.89
- Vanflyta (Drug) $36.07
- VENCLEXTA (Drug) $26.79
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Duarte
Amrita Krishnan, Md, MD
Internal Medicine — Payments: $841,332
Internal Medicine $841,332
Dr. Daneng Li, M.d, M.D
Internal Medicine — Payments: $584,406
Internal Medicine $584,406
Alexey Danilov, M.d, M.D
Internal Medicine — Payments: $419,324
Internal Medicine $419,324
Marwan Fakih, Md, MD
Internal Medicine — Payments: $355,683
Internal Medicine $355,683
Dr. Tycel Phillips, M.d, M.D
Internal Medicine — Payments: $336,879
Internal Medicine $336,879
Haris Ali, M.d, M.D
Internal Medicine — Payments: $293,846
Internal Medicine $293,846